Puma Biotechnology, INC Form 4 insider transactions

Director Troy Wilson sold 27,000 shares of Puma Biotechnology (PBYI) common stock on June 13, 2024, at a weighted average price of $3.3297.

Brian M. Stuglik, a director at Puma Biotechnology, sold 9,900 shares of common stock at an average price of $3.3867 on June 13, 2024, under a pre-arranged 10b5-1 trading plan.

Adrian Senderowicz, a director at Puma Biotechnology, sold 27,000 shares of common stock at a weighted average price of $3.3266 on June 13, 2024, under a pre-arranged 10b5-1 trading plan.

Director Jay M. Moyes of Puma Biotechnology sold 22,000 shares of common stock on June 13, 2024, at a weighted average price of $3.3394.

Allison Dorval, a director at Puma Biotechnology, sold 11,000 shares of common stock at an average price of $3.3724 on June 13, 2024, under a pre-arranged 10b5-1 trading plan.

Alan Auerbach, CEO of Puma Biotechnology, received additional equity awards to correct a calculation error in the original annual equity grants.